Last reviewed · How we verify
Tipifarnib;Zarnestra; R115777
Tipifarnib;Zarnestra; R115777 is a Farnesyltransferase inhibitor Small molecule drug developed by Johnson & Johnson Pharmaceutical Research & Development, L.L.C.. It is currently in Phase 3 development for Acute myeloid leukemia, Basal cell carcinoma.
Tipifarnib is a farnesyltransferase inhibitor that blocks the farnesylation of Ras proteins, which are involved in cell signaling and proliferation.
Tipifarnib is a farnesyltransferase inhibitor that blocks the farnesylation of Ras proteins, which are involved in cell signaling and proliferation. Used for Acute myeloid leukemia, Basal cell carcinoma.
At a glance
| Generic name | Tipifarnib;Zarnestra; R115777 |
|---|---|
| Sponsor | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. |
| Drug class | Farnesyltransferase inhibitor |
| Target | Farnesyltransferase |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
By inhibiting farnesyltransferase, tipifarnib prevents the post-translational modification of Ras proteins, which are often mutated and constitutively active in various cancers. This leads to the inhibition of cell proliferation and induction of apoptosis in cancer cells.
Approved indications
- Acute myeloid leukemia
- Basal cell carcinoma
Common side effects
- Fatigue
- Nausea
- Diarrhea
- Vomiting
- Anemia
- Thrombocytopenia
- Neutropenia
- Leukopenia
Key clinical trials
- Tipifarnib and Naxitamab for Relapsed/Refractory Neuroblastoma (PHASE2)
- Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorders (The Pediatric MATCH Screening Trial) (PHASE2)
- Combination Trial of Tipifarnib and Alpelisib in Adult Recurrent/ Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC) (PHASE1, PHASE2)
- Tipifarnib for the Treatment of Advanced Solid Tumors, Lymphoma, or Histiocytic Disorders With HRAS Gene Alterations, a Pediatric MATCH Treatment Trial (PHASE2)
- Expanded Access to Tipifarnib
- Tipifarnib in Advanced Squamous NSCLC With Oncogen HRAS MutAtionS (PHASE2)
- Tipifarnib in Subjects With Myelodysplastic Syndromes (PHASE2)
- Tipifarnib in Subjects With Chronic Myelomonocytic Leukemia, Other MDS/MPN, and Acute Myeloid Leukemia (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Tipifarnib;Zarnestra; R115777 CI brief — competitive landscape report
- Tipifarnib;Zarnestra; R115777 updates RSS · CI watch RSS
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C. portfolio CI
Frequently asked questions about Tipifarnib;Zarnestra; R115777
What is Tipifarnib;Zarnestra; R115777?
How does Tipifarnib;Zarnestra; R115777 work?
What is Tipifarnib;Zarnestra; R115777 used for?
Who makes Tipifarnib;Zarnestra; R115777?
What drug class is Tipifarnib;Zarnestra; R115777 in?
What development phase is Tipifarnib;Zarnestra; R115777 in?
What are the side effects of Tipifarnib;Zarnestra; R115777?
What does Tipifarnib;Zarnestra; R115777 target?
Related
- Drug class: All Farnesyltransferase inhibitor drugs
- Target: All drugs targeting Farnesyltransferase
- Manufacturer: Johnson & Johnson Pharmaceutical Research & Development, L.L.C. — full pipeline
- Therapeutic area: All drugs in Oncology
- Indication: Drugs for Acute myeloid leukemia
- Indication: Drugs for Basal cell carcinoma
- Compare: Tipifarnib;Zarnestra; R115777 vs similar drugs
- Pricing: Tipifarnib;Zarnestra; R115777 cost, discount & access